Recruiting studies: Transthyretin Related Attr Familial Amyloid Cardiomyopathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Phase N/A · 40 location(s) · Alnylam Pharmaceuticals · NCT04561518 A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3 · 14 location(s) · Intellia Therapeutics · NCT06672237 MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Phase 3 · 132 location(s) · Intellia Therapeutics · NCT06128629 Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients Wit
Phase N/A · 1 location(s) · University of Texas Southwestern Medical Center · NCT07196839 Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Phase N/A · 3 location(s) · University of Texas Southwestern Medical Center · NCT05489549 Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · 82 location(s) · AstraZeneca · NCT06465810 Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Phase N/A · 4 location(s) · Intellia Therapeutics · NCT05697861 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Patho
Phase 3 · 103 location(s) · Eidos Therapeutics, a BridgeBio company · NCT06563895

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.